Medical School
- MD, Duke University School of Medicine (2007)
Graduate School
- PhD, Duke University (2007)
Undergraduate School
- BS, Cornell University (NY) (1999)
Internship
- Massachusetts General Hospital Program (2008)
Residency
- Massachusetts General Hospital Program, Neurosurgery (2013)
Fellowships
- Massachusetts General Hospital/Dana-Farber Cancer Institute/Children's Hospital Boston Program, Neurological Surgery
Department
NeurosurgeryProfessional Titles
- Chair, Department of Neurosurgery
Research Interests
Dr. Fecci's research in the Fecci Lab focuses on reversing tumor-imposed immune dysfunction and on developing novel immune-based platforms for primary and metastatic brain tumors, as well as other solid cancers.Publications
- Qazi JJ, Van Swearingen AED, Carpenter DJ, Broadwater G, Leng JX, Arshad M, Chmura SJ, Bansal R, Alder L, Fecci PE, Kirkpatrick JP, Salama JK, Mullikin TC, Floyd SR, Anders CK. Impact of systemic therapy after stereotactic radiosurgery in patients with limited brain-only metastasis. Neurooncol Adv. 2025 Jan-Dec;7(1):vdaf214. PubMed PMID: 41497447
- Zhao J, Vaios E, Calabrese E, Yang Z, Ginn J, Gonzalez A, Floyd S, Reitman ZJ, Fecci P, Kirkpatrick J, Lafata KJ, Wang C. An Explainable Deep Model for Risk Scoring and Accurate Radionecrosis Identification Following Brain Metastasis Stereotactic Radiosurgery. Int J Radiat Oncol Biol Phys. 2025 Nov 27. [Epub ahead of print] PubMed PMID: 41317799
- Hoyt-Miggelbrink AM, Waibl Polania J, Wachsmuth L, Lorrey S, Mohan A, Hardigan A, Blandford E, Lerner E, Wilkinson D, Hotchkiss KM, Cook S, Hemmers S, Patel A, Ayasoufi K, Fecci P. Upregulation of TNFR2 Precedes TOX Expression by Exhausted T cells and Restricts Antitumor and Antiviral Immunity. Clin Cancer Res. 2025 Nov 21. [Epub ahead of print] PubMed PMID: 41269210
- Walton CM, Bell M, O'Neil R, Sahin O, Choi BD, Fecci PE, Strickland BA. Chimeric antigen receptor (CAR) T-cell therapy for glioblastoma (GBM): current clinical insights, challenges, and future directions. J Immunother Cancer. 2025 Oct 31;13(10). PubMed PMID: 41176315
- Singh K, Foster MW, Violette MJ, Corcoran AM, Hotchkiss KM, Railton CO, Blandford EE, Blethen KE, Thomas EL, McIntosh WC, Ashley DM, Desjardins A, Friedman HS, Johnson MO, Friedman A, Keir S, Buckley ED, Herndon JE, McLendon RE, Sampson JH, Calabrese E, López GY, Grant GA, Patel AP, Gregory SG, Li CY, Fecci PE, Khasraw M. A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8( ) infiltration in glioma. Sci Rep. 2025 Oct 23;15(1):37112. PubMed PMID: 41131134
- Sharma A, Boyce Kennedy L, Van Swearingen AED, Ahluwalia MS, Bagley SJ, Chiang VL, Chung C, Cittelly DM, Daras M, Davies MA, Fecci PE, Haas-Kogan DA, Hattangadi-Gluth JA, Jerzak KJ, Kim MM, Malani R, Mehta MP, Moss NS, Neman J, Nguyen DX, Priceman SJ, Sahebjam S, Shih HA, Soffietti R, Wang N, Zimmer A, Goldberg S, Khasraw M, Anders CK, Lin NU. Intracranial metastases from solid tumors: Call to Action and Consensus from the Society for Neuro-Oncology and American Society of Clinical Oncology Collaborative. Neuro Oncol. 2025 Oct 1. [Epub ahead of print] PubMed PMID: 41051254
- Singh K, Hotchkiss KM, Cook SL, Noldner P, Zhou Y, Moelker EM, Railton CO, Blandford EE, Puviindran BJ, Wallace SE, Norberg PK, Archer GE, Shaz BH, Ayasoufi K, Sampson JH, Khasraw M, Fecci PE. IL-7-mediated expansion of autologous lymphocytes increases CD8( ) VLA-4 expression and accumulation in glioblastoma models. bioRxiv. 2025 Apr 14. PubMed PMID: 41031006
- Graham-Gurysh EG, Woodring RN, Simpson SR, Mendell SE, Lukesh NR, Pena ES, Moore KM, Ontiveros-Padilla LA, Hendricksen AT, Lopez AM, Williamson GL, Murphy CT, Genito CJ, Hipp KA, Singh G, Zamboni WC, Hingtgen SD, Fecci PE, Bachelder EM, Ainslie KM. Post-resection delivery of a TLR7/8 agonist from a biodegradable scaffold achieves immune-mediated glioblastoma clearance and protection against tumor challenge in mice. Nat Commun. 2025 Sep 29;16(1):8603. PubMed PMID: 41022761
- Puviindran BJ, Wallace S, Ayasoufi K, Lerner E, Fecci PE. Within and beyond the tumor: Mechanisms of glioblastoma-induced immunosuppression. Neurooncol Adv. 2025 Sep;7(Suppl 4):iv4-iv18. PubMed PMID: 40933031
- Mariani CL, Wachsmuth LP, Bramall AN, Meritet DM, Hatfield J, Tsvankin V, Keenihan EK, Tokarz DA, Tyc R, Nolan MW, Fecci PE. Adapting Laser Interstitial Thermal Therapy for the Treatment of Naturally Occurring Intracranial Tumors in Dogs. Clin Cancer Res. 2025 Oct 15;31(20):4372-4382. PubMed PMID: 40801892
- Haskell-Mendoza AP, Gonzalez AT, Reason EH, Jackson JD, Seas A, Mohan AA, Zaidi SE, Lerner EC, Srinivasan ES, Bradbury C, Herndon JE, Goodwin CR, Fecci PE. Disparities in clinical trial enrollment related to laser interstitial thermal therapy for central nervous system metastases. Neurosurg Rev. 2025 Jul 22;48(1):575. PubMed PMID: 40691370
- Zhao J, Vaios E, Calabrese E, Yang Z, Robertson S, Ginn J, Lu K, Yin FF, Reitman Z, Kirkpatrick J, Floyd S, Fecci P, Wang C. A Radiogenomic Deep Ensemble Learning Model for Identifying Radionecrosis Following Brain Metastases (BM) Stereotactic Radiosurgery in Patients With Non-small Cell Lung Cancer BM. Adv Radiat Oncol. 2025 Aug;10(8):101826. PubMed PMID: 40686742
- Landazuri P, Cheng JJ, Leuthardt E, Kim AH, Southwell DG, Fecci PE, Neimat J, Sun D, Lega B, Panov F, Chiang V, Abel T, Ben-Haim S, Piccioni DE, Shih JJ, Palys V, Rodriguez A, Bandt SK, Petronio J, Lacroix M, Baumgartner J. Interstitial Thermal Therapy in Mesial Temporal Lobe Epilepsy. JAMA Neurol. 2025 Sep 1;82(9):915-924. PubMed PMID: 40622685
- Neff C, Price M, Ballard CAP, Cioffi G, Liu Z, Walsh R, Barnholtz-Sloan JS, Walsh KM, Salama AKS, Anders CK, Fecci PE, Ostrom QT. Atopy Improves Survival and Decreases Risk of Brain Metastasis in Cutaneous Melanoma. Cancer Epidemiol Biomarkers Prev. 2025 Sep 2;34(9):1600-1608. PubMed PMID: 40548861
- Seidel JA, Alder L, Salama AKS, Anders CK, Komisarow J, Fecci PE, Sperduto P, Mullikin T, Kirkpatrick JP, Floyd SR, Reitman ZJ, Vaios EJ. Management outcomes for biopsy-proven radiation necrosis in patients with brain metastases in the era of immune-checkpoint blockade. J Neurooncol. 2025 Oct;175(1):199-208. PubMed PMID: 40522563
- Wachsmuth LP, Srinivasan ES, Puviindran BJ, Haskell-Mendoza AP, DeSpenza T, Fecci PE. Autonomic modulation of the immune response and implications for CNS malignancies. NPJ Precis Oncol. 2025 Jun 7;9(1):168. PubMed PMID: 40483275
- Mehari M, Warrier G, Dada A, Kabir A, Haskell-Mendoza AP, Tripathy A, Jha R, Nieblas-Bedolla E, Jackson JD, Gonzalez AT, Reason EH, Flusche AM, Reihl S, Dalton T, Negussie M, Gonzales CN, Ambati VS, Desjardins A, Daniel AGS, Krishna S, Chang S, Porter A, Fecci PE, Hollon T, Chukwueke UN, Badal K, Molinaro AM, Hervey-Jumper SL. Predicting therapeutic clinical trial enrollment for adult patients with low- and high-grade glioma using supervised machine learning. Sci Adv. 2025 Jun 6;11(23):eadt5708. PubMed PMID: 40465719
- Eckert T, Walton C, Bell M, Small C, Rowland NC, Rivers C, Zukas A, Lindhorst S, Fecci P, Strickland BA. The Basis for Targeting the Tumor Macrophage Compartment in Glioblastoma Immunotherapy. Cancers (Basel). 2025 May 12;17(10). PubMed PMID: 40427130
- Singh K, Hotchkiss KM, Cook SL, Noldner P, Zhou Y, Moelker EM, Railton CO, Blandford EE, Puviindran BJ, Wallace SE, Norberg PK, Archer GE, Shaz BH, Ayasoufi K, Sampson JH, Khasraw M, Fecci PE. IL-7-mediated expansion of autologous lymphocytes increases CD8 VLA-4 expression and accumulation in glioblastoma models. J Clin Invest. 2025 Jun 16;135(12). PubMed PMID: 40244705
- Zachem TJ, Sperber JE, Chen SF, Adil SM, Wissel BD, Chamberlin G, Owolo E, Nguyen A, Crowell KA, Herndon JE 2nd, Abi Hachem R, Jang DW, Cummings TJ, Johnson MO, Eward W, Patel AP, Komisarow JM, Cook SH, Southwell D, Fecci PE, Friedman AH, Goodwin CR, Codd PJ. Intraoperative brain tumor classification via laser-induced fluorescence spectroscopy and machine learning. J Neurosurg. 2025 Aug 1;143(2):313-322. PubMed PMID: 40184679
- Zhao J, Vaios E, Yang Z, Lu K, Floyd S, Yang D, Ji H, Reitman ZJ, Lafata KJ, Fecci P, Kirkpatrick JP, Wang C. Radiogenomic explainable AI with neural ordinary differential equation for identifying post-SRS brain metastasis radionecrosis. Med Phys. 2025 Apr;52(4):2661-2674. PubMed PMID: 39878595
- Waibl Polania J, Hoyt-Miggelbrink A, Tomaszewski WH, Wachsmuth LP, Lorrey SJ, Wilkinson DS, Lerner E, Woroniecka K, Finlay JB, Ayasoufi K, Fecci PE. Antigen presentation by tumor-associated macrophages drives T cells from a progenitor exhaustion state to terminal exhaustion. Immunity. 2025 Jan 14;58(1):232-246.e6. PubMed PMID: 39724910
- Haskell-Mendoza AP, Gonzalez AT, Reason EH, Flusche AM, Chongsathidkiet P, Wachsmuth LP, Goodwin CR, Fecci PE. The LITT Fit in neuro-oncology: indications, imaging, and adjunctive therapies. J Neurooncol. 2025 Mar;172(1):1-11. PubMed PMID: 39585599
Practice Locations
UCHealth Neurosciences Center - Anschutz Medical Campus1635 Aurora Ct
4th Floor
Aurora, CO 80045
720-848-2080
Hospital Affiliation
- UCHealth Memorial Hospital
Specialty Information
Specialties- Neurological Surgery
Clinical Interests
• Astrocytomas • Brain Tumors • Dermoid and Epidermoid • Ependymoma • Glioblastoma Multiforme (GBM) • Gliomas • Hemangioblastoma • Metastatic Brain Tumor • Radiation Necrosis
Care Philosophy
Peter Fecci MD, PhD, is currently Professor and Chair of the Department of Neurosurgery at the University of Colorado Anschutz. As a neurosurgeon-scientist, he likewise holds graduate appointments in the Departments of Immunology, Cancer Biology, Pharmacology, and Bioengineering. Dr. Fecci’s clinical focus lies with intrinsic brain tumors, such as gliomas and metastases. In addition to performing complex open surgeries that include awake and asleep mapping procedures, he has built one of the country’s largest programs for Laser Interstitial Thermal Therapy (LITT) as a minimally invasive alternative option for brain tumors. He performed some of the first LITT cases for brain tumor treatment at UCHealth. Dr. Fecci is a recipient of the Cancer Research Institute Lloyd J. Old STAR Award, the Sontag Distinguished Scientist and Distinguished Alumni Awards, and is an inductee into the American Society for Clinical Investigation (ASCI) and the American Academy of Neurological Surgeons.
• Astrocytomas • Brain Tumors • Dermoid and Epidermoid • Ependymoma • Glioblastoma Multiforme (GBM) • Gliomas • Hemangioblastoma • Metastatic Brain Tumor • Radiation Necrosis
Care Philosophy
Peter Fecci MD, PhD, is currently Professor and Chair of the Department of Neurosurgery at the University of Colorado Anschutz. As a neurosurgeon-scientist, he likewise holds graduate appointments in the Departments of Immunology, Cancer Biology, Pharmacology, and Bioengineering. Dr. Fecci’s clinical focus lies with intrinsic brain tumors, such as gliomas and metastases. In addition to performing complex open surgeries that include awake and asleep mapping procedures, he has built one of the country’s largest programs for Laser Interstitial Thermal Therapy (LITT) as a minimally invasive alternative option for brain tumors. He performed some of the first LITT cases for brain tumor treatment at UCHealth. Dr. Fecci is a recipient of the Cancer Research Institute Lloyd J. Old STAR Award, the Sontag Distinguished Scientist and Distinguished Alumni Awards, and is an inductee into the American Society for Clinical Investigation (ASCI) and the American Academy of Neurological Surgeons.